Efficacy and Safety of Antioxidant Treatment With {alpha}-Lipoic Acid Over 4 Years in Diabetic Polyneuropathy: The NATHAN 1 Trial Full Text
Diabetes Care,

Ziegler D et al. – Four–year treatment with α–lipoic acid (ALA) in mild–to–moderate diabetic distal symmetric sensorimotor polyneuropathy (DSPN) did not influence the primary composite end point but resulted in a clinically meaningful improvement and prevention of progression of neuropathic impairments and was well tolerated. Because the primary composite end point did not deteriorate significantly in placebo subjects, secondary prevention of its progression by ALA according to the trial design was not feasible.

Methods
  • In a multicenter randomized double–blind parallel–group trial, 460 diabetic patients with mild–to–moderate DSPN were randomly assigned to oral treatment with 600 mg ALA four times daily (n = 233) or placebo (n = 227) for 4 years.
  • Primary end point was a composite score (Neuropathy Impairment Score [NIS]–Lower Limbs [NIS–LL] and seven neurophysiologic tests).
  • Secondary outcome measures included NIS, NIS–LL, nerve conduction, and quantitative sensory tests (QSTs).

Results
  • Change in primary end point from baseline to 4 years showed no significant difference between treatment groups (P = 0.105).
  • Change from baseline was significantly better with ALA than placebo for NIS (P = 0.028), NIS–LL (P = 0.05), and NIS–LL muscular weakness subscore (P = 0.045).
  • More patients showed a clinically meaningful improvement and fewer showed progression of NIS (P = 0.013) and NIS–LL (P = 0.025) with ALA than with placebo.
  • Nerve conduction and QST results did not significantly worsen with placebo.
  • Global assessment of treatment tolerability and discontinuations due to lack of tolerability did not differ between the groups.
  • The rates of serious adverse events were higher on ALA (38.1%) than on placebo (28.0%).

Please login or register to follow this author.
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Endocrinology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Endocrinology Articles

1 Effects of 12 weeks high-dose vitamin D3 treatment on insulin sensitivity, beta cell function, and metabolic markers in patients with type 2 diabetes and vitamin D insufficiency – A double-blind, randomized, placebo-controlled trial Metabolism, July 9, 2014    Clinical Article

2 Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis Diabetes Care, October 24, 2014    Clinical Article

3 Seasonal variation in month of diagnosis in children with type 1 diabetes registered in 23 European centers during 1989-2008: little short-term influence of sunshine hours or average temperature Pediatric Diabetes, October 16, 2014    Clinical Article

4 Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator–controlled, adaptive proof-of-concept phase 2 study Diabetes Care, September 19, 2014    Clinical Article

5 Hemoglobin A1c less than 6.5% on admission increases risk for in-hospital and 1-year mortality in patients with diabetes and chest pain Cardiovascular Endocrinology, September 2, 2014    Clinical Article

6 Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the action to control cardiovascular risk in diabetes study) The American Journal of Cardiology, October 3, 2014    Clinical Article

7 New insulin glargine 300 units/ml versus glargine 100 units/ml in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2) Diabetes Care, September 22, 2014    Clinical Article

8 The effects of intravenous insulin infusions on early mortality for patients with acute coronary syndromes who present with hyperglycaemia: A matched propensity analysis using data from the MINAP database 2008–2012 European Heart Journal: Acute Cardiovascular Care, October 1, 2014    Clinical Article

9 Latent autoimmune diabetes in adults with low-titer GAD antibodies: Similar disease progression with type 2 diabetes: A nationwide, multicenter prospective study (LADA China Study 3) Diabetes Care, October 24, 2014    Clinical Article

10 Metformin powder formulation compared to metformin tablets on glycemic control and on treatment satisfaction in subjects with type 2 diabetes mellitus The Journal of Clinical Pharmacology, October 20, 2014    Clinical Article

11 Effects of 12 weeks treatment with fermented milk on blood pressure, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind placebo-controlled study European Journal of Endocrinology, October 13, 2014    Clinical Article

12 Cobalamin status and its relation with depression, cognition and neuropathy in patients with type 2 diabetes mellitus using metformin Acta Diabetologica, October 15, 2014    Clinical Article

13 Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: The LIBRA Trial Diabetes Care, September 26, 2014    Clinical Article

14 Initial combination of linagliptin and metformin compared with linagliptin monotherapy in newly diagnosed type 2 diabetes patients with marked hyperglycaemia: a randomised, double-blind, active-controlled, parallel group, multinational clinical trial Diabetes, Obesity and Metabolism, October 10, 2014    Clinical Article

15 New insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2) Diabetes Care, September 12, 2014    Clinical Article

16 The pharmacokinetics of metformin and concentrations of HbA1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitus British Journal of Clinical Pharmacology, October 9, 2014    Clinical Article

17 An early pregnancy HbA1c ≥5.9% (41 mmol/mol) is optimal for detecting diabetes and identifies women at increased risk of adverse pregnancy outcomes Diabetes Care, September 12, 2014    Clinical Article

18 New insulin glargine 300 units/ml versus glargine 100 units/ml in people with type 2 diabetes using oral agents and basal insulin: Glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2) Diabetes Care, October 23, 2014    Clinical Article

19 The effect of proton pump inhibitors on glycated hemoglobin levels in patients with type 2 diabetes mellitus Canadian Journal of Diabetes, October 28, 2014    Review Article

20 Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus The Journal of Clinical Hypertension, October 24, 2014    Clinical Article

Indexed Journals in Endocrinology: Endocrinology, Journal of Endocrinology, Clinical Endocrinology, Diabetesmore